Photofrin

Company: QLT
Approval Status: Approved January 1998
Treatment for: Non-small cell lung cancer
Areas: Cancer & Oncology

| General Information |

General Information

QLT PhotoTherapeutics' light-activated drug Photofrin (porfimer sodium) was approved for injection in treating early-stage, microinvasive lung cancer. It is approved for use in patients with microinvasive endobronchial non-small cell lung cancer at an early stage, for whom surgery and radiotherapy are not indicated.

< back to top

Photofrin Drug Information

The Photofrin drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.